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 Undesirable and variable behavior in mares related to the estrous cycle is a 
common issue reported in the equine industry, especially for mares in a performance 
setting.  These behaviors can interfere with, as well as decrease, overall performance.  
The objective of this study was to determine if administration of sixty units of oxytocin 
once daily for 29 days, regardless of when treatment was initiated during the estrous 
cycle, would induce prolonged corpus luteum (CL) function in cycling mares. Mares 
were randomly assigned to two groups: 1) saline-treated control (n=7) and 2) oxytocin-
treated (n=9).  Control mares received 3 cc saline and oxytocin-treated mares received 
sixty units (3 cc) of oxytocin intramuscularly (IM) for 29 consecutive days.  Treatment 
was initiated in all mares on the same day, independent of the day of the cycle.  Jugular 
blood samples for determination of progesterone concentration were collected three times 
weekly (M, W, F) for 21 days before treatment was initiated.  Beginning on the first day 
of treatment, blood samples were collected daily for seven days, three times weekly for 
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the remainder of the treatment period, and then three times weekly for 45 days after the 
last treatment.  Mares were considered to have prolonged CL function if serum 
progesterone remained >1.0 ng/mL for at least 30 days during/after the treatment period.  
The proportion of mares with prolonged CL function was higher in the oxytocin-treated 
group compared to the saline-treated group (7/9 vs. 1/7, respectively; P<0.05).   Three of 
the seven oxytocin-treated mares that developed prolonged CL function initially 
underwent luteolysis within three to seven days of the start of oxytocin treatment, and 
then developed prolonged CL function following the subsequent ovulation during the 
treatment period.  In the other four oxytocin-treated mares that developed prolonged CL 
function, progesterone remained >1.0 ng/mL throughout the treatment period and into the 
post-treatment period.  All mares with prolonged CL function maintained elevated 
progesterone concentrations through at least day 56 of the study.  Sixty units of 
exogenous oxytocin treatment for 29 consecutive days was effective in prolonging CL 
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 Undesirable and variable behavior in mares related to the reproductive cycle is a 
common issue reported in the equine industry, especially for female horses in a 
performance setting.  These behaviors can interfere with and decrease, overall 
performance.  The objective of this study was to determine if administration of 60 units 
of the hormone oxytocin once daily for 29 days, regardless of when treatment was 
initiated during the estrous cycle, would induce prolonged corpus luteum function in 
cycling mares.  Mares were randomly assigned to two groups: 1) saline-treated control 
(n=7) and 2) oxytocin-treated (n=9).  Control mares received 3 cc saline and oxytocin-
treated mares received 60 units (3 cc) of oxytocin intramuscularly for 29 consecutive 
days.  Treatment was initiated in all mares on the same day (day 1), independent of the 
day of the cycle.  Jugular blood samples for determination of progesterone concentration 
were collected three times weekly (M, W, F) for 21 days before treatment was initiated.  
Beginning on the first day of treatment, blood samples were collected daily for seven 
days, three times weekly for the remainder of the treatment period, and then three times 
weekly for 45 days after the last treatment.  Mares were considered to have prolonged CL 
function if serum progesterone remained >1.0 ng/mL for at least 30 days during/after the 
treatment period.  The proportion of mares with prolonged CL function was higher in the 
 
vi 
oxytocin-treated group compared to the saline-treated group (7/9 vs. 1/7, respectively; 
P<0.05).   Three of the seven oxytocin-treated mares that developed prolonged CL 
function initially underwent luteolysis within three to seven days of the start of oxytocin 
treatment, and then developed prolonged CL function following the subsequent ovulation 
during the treatment period.  In the other four oxytocin-treated mares that developed 
prolonged CL function, progesterone remained >1.0 ng/mL throughout the treatment 
period and into the post-treatment period.  All mares with prolonged CL function 
maintained elevated progesterone concentrations through at least day 56 of the study.  
Sixty units of exogenous oxytocin treatment for 29 consecutive days was effective in 
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A common complaint of veterinarians, horse owners, and trainers is the variable 
behavior and performance of mares that is related to the estrous cycle (Jorgensen et al., 
1996).  Because of that, suppression of estrous behavior has become a common practice 
in performance mares and the most widely used methods include: 1) administration of 
exogenous progesterone/progestins 2) extending the duration of corpus luteum (CL) 
function, 3) suppressing ovarian follicular activity, and 4) ovariectomy (Vanderwall and 
Nie, 2011).  Of these methods, the most commonly used are administration of exogenous 
progesterone/progestins and prolonging the life of the CL.             
 Administration of altrenogest (ReguMate®, Merck Animal Health), an orally 
active synthetic progestin, is approved, widely used, and is effective in suppressing 
estrous behavior.  The use of ReguMate is considered the “gold standard” of estrus 
suppression in the equine industry.  Unfortunately, the dose of 0.044 milligrams per 
kilogram (mg/kg) is needed daily, and other drawbacks such as expense, need for long 
term administration, and safety concerns of personnel during handling and dosing are 
drawbacks to its use (Squires et al., 1979; Vanderwall, 2012).   Another drawback exists 
in the fact that because altrenogest is a steroid, it is under increased scrutiny for 
administration to animals in performance settings and is not permitted in some countries 
(Hedberg et al., 2006).  It has been reported that an alternative intramuscular (IM) 
administration of compounded preparation of 225 mg, 450 mg, or 500 mg of altrenogest 
blocked estrous behavior for 12, 15, and 30 days respectively (Storer et al., 2009). 




vary. The use of a compounded preparation of altrenogest when a Food and Drug 
Administration (FDA) approved product such as Regumate ® is available may not be 
appropriate, and is not long term enough to be considered an optimal method for estrus 
suppression.  In an effort to eliminate the inconvenience of daily administration, growth-
promoting implants containing progesterone and estradiol labeled for use in cattle have 
been anecdotally reported to be effective.  When tested in horses under controlled 
conditions, the treated horses failed to produce serum progesterone levels above 0.5 
nanograms per milliliter (ng/mL) and did not suppress estrous behavior (McCue, 1997). 
 An alternative to administration of exogenous progesterone and another common 
method of estrous suppression is induction of prolonged CL function.  This allows for 
endogenous secretion of progesterone from the CL to block estrous behavior.  In cycling 
mares, the CL secretes progesterone for approximately two weeks, during which 
progesterone levels are high.  The CL stops functioning when prostaglandin F2α 
(PGF2α) is secreted by the endometrium during luteolysis (Ginther, 2012).  There is 
interest in developing methods of prolonging luteal function as a means of estrus 
suppression because it allows for the natural secretion of progesterone, rather than the 
supplementation of exogenous progesterone/progestins.   
 There are many methods of inducing prolonged CL function, but the most widely 
used method has been insertion of an intrauterine glass ball.  In a study by Nie et al. 
(2003), placement of a 25-35mm sterile glass ball into the uterus following an ovulation 
resulted in prolonged CL function in 7 of 18 (39%) of mares.  In the control group, four 
of 32 mares (13%) spontaneously prolonged CL function.  It is important to note that 
while insertion of an intrauterine glass ball seems effective, three of the seven mares in 
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the treatment group that prolonged luteal function had one or two estrous cycles after 
placement of the glass ball, followed by prolonged CL function.  As a result, the “per-
cycle” basis of prolonged CL function was 7/62 cycles (11%) and compared to the 4/50 
cycles (8%) in non-treated control mares, and that was not significantly different between 
groups.  Placement and removal of the intrauterine marble must be done by a veterinarian 
when the mare is in late estrus, close to ovulation.  Removal must also be done by a 
veterinarian, which is a drawback to this method.  There have also been reports of 
spontaneous fragmentation of the glass ball in the uterine lumen causing deleterious 
consequences (LeBlanc, 2011).  Because of its variable efficacy, placement of an 
intrauterine glass ball does not seem to be a desirable method for suppression of estrus in 
mares, thus the need for a safe, practical, and effective method of prolonging CL 
function.   
 There are numerous other methods of estrus suppression, however, each of the 
methods has different disadvantages that create a need for more research in the field.  
Issues such as cost, reversibility, etc. are also reason for further research.  The industry is 
in need of a safe, effective, and reliable method of estrus suppression.  
 Recently, administration of oxytocin has been shown to be an effective method of 
prolonging CL function, since administration of 60 units of oxytocin once daily on days 7 
to 14 after ovulation induced prolonged CL function in over 60% of treated mares 
(Vanderwall et al., 2012b).  However, the need to know the exact day of ovulation is a 
drawback to the current oxytocin protocol.  We hypothesized that by extending the 
duration of oxytocin administration, treatment could be initiated at any point during the 
estrous cycle (i.e., without knowing the day of ovulation) and still effectively prolong CL 
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function.  Therefore, the objective of this study was to determine if treating mares with 
oxytocin daily for 29 days would result in prolonged CL function.   
 
5 
REVIEW OF LITERATURE 
 
 The effect of the mare’s estrous cycle on behavior and performance is an 
important issue for the equine industry.  Specifically, concern over the potential for 
estrous behavior to adversely affect performance has led to the common practice of estrus 
suppression.  Though there are many methods of estrus suppression that are currently 
being used, there is a definite need for better options.  It is the purpose of this review to 
examine the complexities of the equine estrous cycle; its effects on performance and 
behavior; and the advantages and disadvantages of the general methods of estrus 
suppression that are currently being used.  It will also address the need for new options of 
estrus suppression and how the use of exogenous oxytocin treatment is effective and 
advantageous to the industry.   
Estrous Behavior and Performance 
 
 Suppression of estrus in mares has become a growing necessity within the equine 
industry.  The behaviors associated with estrus have been reported to have a negative 
effect on the training and showing of horses in many disciplines (McCue, 2003).  Today, 
horses are expected to perform at a very high level of skill and the horse’s disposition is a 
very important factor in its ability to perform (Hedberg et al., 2005).  Veterinarians, 
trainers, and horse owners all complain of negative performance in mares that is related 
to the estrous cycle.  A survey of more than 750 veterinarians reflected that 
approximately 90% feel that the estrous cycle affected the performance of mares, with the 
most frequent clinical sign being reported as a change in attitude.  The behaviors 
associated with the estrous cycle can include biting, kicking, tail swishing, difficulty to 
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train, squealing, “horsing”, excess urination and a decrease in performance (Jorgensen et 
al., 1996). 
 It is important to confirm that the observed behavioral problem is, in fact, 
associated with the reproductive cycle of the mare before initiating treatment, as not all of 
the previously mentioned behaviors are necessarily associated with estrus.  Some 
behaviors thought to be associated with estrus can instead be signs of submissive 
behavior, stallion-like behavior, or urogenital discomfort (McDonnell, 1993; McDonnell, 
2000).  Submissive behavior can be mistaken for behaviors related to estrus and usually 
include leaning away from perceived threats, squirting urine, and wringing of the tail.  
Behaviors truly associated with estrous include leaning towards the stallion, relaxed 
lifting motion of the tail, dribbling urine, or a squatting stance (McDonnell, 2000).  
Urogenital discomfort can result in behaviors mistaken for estrus, but are typically a 
result of cystitis or renal disease instead.  Stallion-like behavior may be a result of 
neoplasia of the ovaries or the administration of exogenous anabolic steroids 
(Vanderwall, 2013).  In an effort to correctly diagnose the complaint of estrus-related 
behavior or performance issues related to the reproductive cycle, it is important to take 
into consideration different factors when determining the source and subsequent 
treatment.  It is important to determine if the undesirable behavior is from a reproductive 
or nonreproductive source followed by determining if the behavior is associated with a 
specific phase of the estrous cycle (McDonnell, 2005). 
If the behavior can be pinpointed to a specific phase, then determining if the 
behavior is physical or behavioral is necessary.  Accurate records are needed to aid in 
determining the phase of the reproductive cycle during which the behavior occurs.  A 
 
7 
physical examination is also necessary in order to rule out other contributing medical 
problems (McCue, 2003).  At certain points of the estrous cycle, mares can exhibit 
behavior related to pain or discomfort during the preovulatory period.  During this period, 
the mare has a large ovarian follicle present on the ovary, causing discomfort prior to 
ovulation in some mares.  This discomfort can cause sensitivity to the weight of a rider 
and can vary in severity from subtle to more severe colic-like symptoms (Cox and 
DeBowes, 1987; Pryor and Tibary, 2005).  The use of an ovulatory agent can be 
beneficial for mares experiencing pain due to a large follicle by shortening the time it is 
present. (Vanderwall, 2013).   
Not all mares have compromised performance from underlying physical causes 
during estrus.  Some mares have such profound signs of estrus that the behavior alone 
affects performance.  This can be seen in instances where the animal is under saddle and 
displays “break down” behavior showing estrus in response to nearby horses or other 
stimuli.  This behavior can include a squatting-like pose and the mare will become 
difficult to move away from the stimulus (McDonnell, 2000).  Behaviors such as this may 
not always be evident and can be much subtler.  Owners and trainers have reported that 
the mare can be simply less attentive or cooperative during estrus, creating difficulty for 
training and showing purposes (McDonnell, 1997).  
In some cases, mares display abnormal estrous behavior and exhibit signs of 
estrus during the anovulatory season, silent estrus, or split estrus. Split estrus can be 
defined as a period during normal estrus with alternating days of receptivity to the 
stallion.  The mare may be receptive one day and non-receptive the next.  This is typical 
in approximately 5% to 12% of mares (Asa, 1986; Ginther, 1992).  Silent estrus is 
 
8 
characterized by the incidence of ovulation without the subsequent behavior reported in 
conjunction with estrus.  This phenomenon occurs in 6%-7.5% of the cycles (Cummings, 
1942; McCaughey et al., 1973). 
There are numerous situations in which the behaviors associated with the estrous 
cycle create difficulty for horse owners, trainers, and veterinarians.  Some mares become 
more difficult than others, and as stated above, there are many situations that differ in 
severity.  Overall, the effect of ovarian activity in the mare, specifically in the phase of 
estrus, has been considered a factor in the decreased performance of the mare (Pryor and 
Tibary, 2005).  For these circumstances, estrus suppression is recommended. 
 
The Estrous Cycle 
 
 
 In order to better understand the necessity of suppression of some behaviors 
related to the estrous cycle, a comprehensive review of mare reproductive anatomy and 
physiology, in addition to an explanation of the estrous cycle is warranted.  
Anatomy and Physiology 
 To understand the physiology of the mare’s reproductive system and estrous 
cycle, it is important to understand some basics of reproductive anatomy of the horse.  
The major female reproductive organs include the ovaries, internal tubular genitalia 
(oviducts, uterus, cervix, vagina, and vestibule) and external genitalia (vulva and labia), 
as well as the mammary glands.  The normal function of these structures is dependent on 
hormones and interactions with their appropriate receptor.  The neuroendocrine hormones 
that are produced or secreted mainly from the hypothalamus and pituitary gland are 
especially important.  Feedback mechanisms between the central nervous system and 
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reproductive organs allow for communication among themselves, thus the endocrine 
system plays an important role in regulating and modulating the reproductive events that 
occur in the mare (Samper, 2009). 
 The ovaries include the following structures:  follicles, corpora lutea, and oocytes.  
These structures are all important to the cyclicity of the mare.  During development, the 
ovaries develop near the kidneys and have only migrated slightly in adulthood.  The 
ovaries are approximately 4-8 centimeters (cm) in length, 3-6 cm in width, and 3-5 cm in 
height.  They lie near the kidneys in the dorsal part of the abdomen, near the iliac wings 
of the hip.  The left ovary is typically more caudal than the right, a result of the left 
kidney also being more caudal.  In prepubertal fillies, the ovaries are oval with the cortex 
and germinal epithelium being superficial.  As the filly approaches puberty, the ovary 
transforms into a kidney bean shape.  This is a result of the ovarian cortex invaginating 
into the medulla (Samper, 2009).  The ovaries occur bilaterally, adjacent to the distal end 
of each uterine horn. 
 Within the ovary, structures known as follicles are present.  These follicles occur 
in a variety of stages including growing, ovulating, anovulatory hemorrhagic, and 
regressing.  Follicular development in the ovaries occurs in a wave-like fashion through 
the different stages of the estrous cycle, seasonal transition, and pregnancy (Ginther, 
1992; Ginther et al., 2004) 
 During the physiological breeding season (i.e., ovulatory season) waves of 
follicular development can be classified as major or minor waves, with the major waves 
being further classified as primary or secondary.  This distinction is based on whether the 
largest follicle produced in a wave reaches ≥30 millimeters (mm) or <30 mm.  Both 
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waves have a growth phase in which a group of follicles begins.  Only major waves 
display selection of a dominant follicle, while minor waves lack a dominant follicle and, 
therefore, no selection.  Major primary waves, also known as ovulatory, are associated 
with the follicular phase, or estrus.  Major secondary waves, which can be ovulatory or 
anovulatory, or minor waves are typically associated with the luteal phase, or diestrus.  
Mares in transition (spring or fall) will typically display a combination of anovulatory 
major follicles and minor follicular waves.  In a typical follicular wave during the estrous 
cycle, 5-10 follicles (4-6 mm) will develop within 2-3 days of each other.  These follicles 
will increase in size by 2-4 mm/day until the largest reaches 20-25mm, signaling the end 
of the growth phase.  Following the growth phase, numerous outcomes can occur.  In a 
minor wave, all of the follicles will regress, but in the case of a major wave, all but one of 
the follicles will regress.  As the subordinate follicles decrease in diameter, the dominant 
follicle increases in diameter until it ovulates, becomes anovulatory, or regresses 
(Samper, 2009).   
After ovulation, the process of follicular rupture and release of the oocyte, the site 
of the dominant follicle begins to fill in with luteal cells.  This process is called 
luteinization and involves the morphogenesis of estrogen producing cells of the follicle 
into progesterone-producing luteal cells that make up the CL (Figure 1; Ginther, 1992).  
The CL plays a significant role in the estrous cycle of the mare, with its main function 
being the secretion of progesterone.  In non-pregnant mares, the CL secretes progesterone 
for approximately two weeks after ovulation, or the duration of diestrus.  The CL ceases 
function when the endometrium secretes PGF2α and luteolysis occurs (Ginther, 2012).  







Figure 1.  A drawing of a cross section of an ovary (Samper, 2009). 
 
The Estrous Cycle 
 
Mares are considered to be a seasonally polyestrous species and usually have a 
20-22 day cycle during the breeding season.  During this cycle, 14-15 days are in the 
luteal phase, also known as diestrus.  Estrus, or the follicular phase, is typically observed 
for 5-7 days, but can range in variation from 3-12 days (Pryor and Tibary, 2005).   
 During the period of estrus, the mare is receptive to the stallion.  Behavioral estrus 
occurs as a result of the circulating estrogen that is associated with the dominant follicle 
being developed in the ovary.  Importantly, progesterone is low at this time, as 
progesterone overrides the effect of estrogen.  The intensity of estrous behavior typically 
becomes stronger as ovulation approaches.  This phenomenon of behavior corresponds 
with physiological events including the dominant follicle reaching maximum size, peak 
concentrations of estradiol 1-3 days before ovulation, and endometrial edema.  After 
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ovulation, estrous behavior will typically decrease simultaneously with the decrease in 
circulating estrogen, and the increase of circulating progesterone associated with the 
development of the CL occurs.  It is typical for estrous behavior to continue for 1-2 days 
after ovulation (Samper, 2009).   
 Ovulation marks the end of one inter-ovulatory interval and the beginning of 
another.  The time between ovulations is typically referred to as the interovulatory 
interval.  The day of ovulation is referred to as Day 0 to serve as a point of reference and 
aid in the prescription of timed treatments (Samper, 2009).   
 The ovulatory season typically begins in response to an increase in day length.  
This change in light is recognized by photoreceptors in the eye and relayed to the pineal 
gland, where changes in melatonin secretion decrease, resulting in increased 
gonadotropin releasing hormone (GnRH) synthesis and secretion.  GnRH then stimulates 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) synthesis via the 
pituitary gland, which reaches the ovaries and stimulates follicular growth (Bergfelt, 
2009).  This interaction is known as the hypothalamic-pituitary-ovarian (HPO) axis 
(Figure 2).  It is important to understand the HPO axis and the effect it has on 
progesterone and estrogen during the estrous cycle.   
 The high concentrations of circulating estradiol typically peak before ovulation.  
These levels of estradiol have a positive feedback on the HPO axis and an increase in LH 
during late estrus occurs as a result.  The high concentrations of LH that occur are needed 
for the dominant follicle to continue growing and also serves as a signal for the coming 
ovulation of the follicle (Bergfelt and Adams, 2007).  At the time of ovulation, FSH is 
low as a result of the negative synergistic effect of inhibin and estradiol (Samper, 2009).  
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It will begin to rise as LH and follicular inhibin fall after ovulation.  LH is still needed in 
low magnitude surges for growth and maturation of the CL and increases circulating 
progesterone.  Follicle stimulating hormone and progesterone will remain high during 
diestrus and the presence of the CL, but will decrease near the end of diestrus as the CL 




Figure 2.  Seasonal influences on the hormonal and behavioral interactions associated 










Figure 3. Hormonal profiles and associated ovarian activity during the equine estrous         








The phenomenon of luteolysis is also known as the cessation of the luteal phase, 
or regression of the CL.  After day 14 of the mare’s cycle, progesterone levels decrease 
dramatically.  This event takes place as a result of the pulsatile release of uterine PGF2α.  
The combination of the decrease in progesterone and frequent pulses of PGF2α allows 
the mechanism of luteolysis to take place.  The process of luteolysis is finished by 
approximately Day 17 of the mare’s cycle or when progesterone concentrations are <2 
ng/mL (Samper, 2009).  This typically occurs as a result of the absence of an embryonic 
vesicle that otherwise would block a complex mechanism of events leading to the 
endometrial secretion of PGF2α and the subsequent disappearance of the CL (Samper, 
2009).  From an evolutionary standpoint, luteolysis appears to have evolved as a means to 
allow mammals to increase their reproductive efficiency.  This process allows the animal, 
if it did not conceive, to have a short period of time (diestrus) where progesterone is 
secreted, resulting in a reduction of cyclic activity and quiescence of the myometrium.  
Following this time, the CL is removed via the process of luteolysis, and a new 
reproductive cycle can begin (McCracken, 1999).  
Uterine Role in Luteolysis 
 
The uterus plays an important role in luteolysis and is responsible for the 
mechanisms that allow the CL to persist or regress (Ginther, 1990).  Regression of the CL 
occurs as a result of pulsatile secretion of PGF2α from the endometrium, which also 
brings about the end of diestrus (Alcantara et al., 2005).  As previously mentioned, the 
decline of progesterone is a hallmark characteristic of luteolysis, as well as the transition 
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of the CL into the subsequent structure known as the corpus albicans (McCracken, 1999).   
The mechanism of luteolysis has been studied in humans, as well as horses and other 
livestock animals.  Interestingly, the process of luteolysis is different for each species, 
with horses being especially different from other livestock animals.  These differences 
begin with the pulses of PGF2α, which are measured in the blood by detecting amounts 
of the primary systemic metabolite of PGF2α, 13,14-dihydro-15-keto PGF2α (PGFM).  
PGFM is measured in the blood as a result of PGF2α having a very short half-life, thus 
making it hard to measure, as opposed to PGFM, which is commonly measured in 
research settings because it is longer lasting and presents an accurate representation of 
circulating PGF2α (Ginther, 2012).   
There is a distinct difference in the route of PGF2α transport between mares and 
ruminants.  The transport of PGF2α from the uterus to the CL in mares differs due to 
PGF2α being transported from the uterus to the ovaries via whole-body (i.e., systemic) 
circulation, differing from cattle and the local transport and effectiveness of PGF2α via 
countercurrent exchange from the utero-ovarian vein to the ovarian artery.  This occurs in 
ruminants as a result of the venous and lymphatic vessels of the uterine horn passing 
along the ovarian pedicle in close proximity to the ovarian artery.  PGF2α, which is fat 
soluble, passes through the walls of the uterine vessels and the ovarian artery, which are 
near each other, thus countercurrent exchange and local delivery of PGF2α to the ovary 
and CL, is achieved (Ginther et al., 1972). 
Mares, differing from ruminants, do not have the proximity of uterine vessels and 
ovarian artery needed in order to achieve counter current exchange of PGF2α.  The 
ovarian artery lacks major contact with the uterine vein and thus the secretion of PGF2α 
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and action on the CL takes place systemically (Ginther et al., 1972). This phenomenon 
has been established by various studies, which had the common goal of establishing the 
systemic route of PGF2α in the mare. Douglas et al. (1975a) used three different doses of 
PGF2α (0, 0.25, or 1.25 mg) and 3 different routes of administration of PGF2α in order to 
better understand the luteolytic effect of PGF2α.  They found that there was no 
significant difference between the administrations of PGF2α locally or systemically. 
Ginther and First (1971) found that the CL was maintained despite partial hysterectomy 
and no difference in whether the contralateral or ipsilateral tissue to the CL was removed.  
Further studies by Ginther included the observation of the unilateral relationship of the 
embryo and uterus in ruminant animals versus mares.  Mares displayed a relationship 
between uterus and embryo that allowed for the CL to be maintained while the embryo 
moved to different locations within the uterus.  This movement differs from the stationary 
location of the embryo in ruminants and further solidified that the unilateral utero-ovarian 
relationship and intrauterine effectiveness of PGF2α is effective in ruminants, but not 
mares (Ginther et al., 2009) 
Role of oxytocin in luteolysis 
 
 As previously mentioned, in mares, as well as many other domestic animals, 
PGF2α is secreted in a pulsatile fashion during luteolysis.  PGF2α is considered to be 
responsible for luteolysis in equines and induces luteolysis in both the diestrus period and 
early pregnancy in mares (Douglas and Ginther, 1972).  The mechanisms that lead to the 
secretion of PGF2α release in mares are not fully understood, however, in domestic 
ruminants, it is known that the release of PGF2α from the endometrium is induced by the 
action of oxytocin, likely from the posterior pituitary, on endometrial oxytocin receptors 
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(Silvia et al., 1991). The development of these oxytocin receptors is dependent on the 
circulating presence of steroid hormones (Vallet et al., 1990).  During late diestrus, 
estrogen interacts with the uterus, which has been primed by progesterone, and increases 
the amount of oxytocin receptors present (Zhang et al., 1992).  The PGF2α that is 
secreted as a result of the action of oxytocin from the posterior pituitary then stimulates 
the secretion of oxytocin from the corpus luteum (Flint and Sheldrick, 1982).  This order 
of events creates a positive feedback loop, which subsequently results in an increased 
production of PGF2α, creating the characteristic spike in PGF2α needed for luteolysis.  
Although it is not fully understood in the equine species, it is thought that oxytocin does 
play a role in the luteolytic process in mares.  
 As research has continued on the role of oxytocin in mares, it has become 
generally accepted that oxytocin plays an important role in the secretion of PGF2α.  The 
origin of oxytocin related to luteolysis in mares is thought to be from the posterior 
pituitary (Vanderwall et al., 1998) and/or from the endometrium (Stout et al., 2000), but 
not from the CL (Stevenson et al., 1991).  The oxytocin secreted from both sources 
stimulates the secretion of uterine PGF2α, and additional oxytocin is released in response 
to PGF2α, thus creating a positive feedback loop.  This positive feedback mechanism is 
thought to be involved in the multiple large pulses of PGF2α that are observed during 
luteolysis (Stout, 2011).     
 It has been found that each pulse of PGF2α during luteolysis is also associated 
with a pulse of oxytocin, which supports the general consensus that oxytocin plays a key 
role in equine luteolysis (Ginther and Beg, 2009).  Other studies that have contributed to 
the theory include examples such as Betteridge et al. (1985) who found that oxytocin 
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administered during late diestrus results in a rapid increase of plasma PGFM, as well as a 
study by Goff et al., (1987) which established that PGFM levels in response to oxytocin 
reach a maximum near the time of luteolysis.  Subsequent studies demonstrated that the 
late diestrus increase in oxytocin responsiveness correlated with an increase in the 
binding capacity of endometrial oxytocin receptors (Starbuck et al., 1998; Sharp et al., 
1997).   
 In nonpregnant mares, there is a corresponding rise in the ability of the 
endometrium to secrete PGF2α in response to oxytocin, and an increase in the 
concentration of oxytocin receptors at the end of diestrus (Starbuck et al., 1998).  Both 
are high between days 10-15 post ovulation, however, in contrast to this phenomenon, 
prior to day 10, the concentration of endometrial oxytocin receptors and enzymes 
necessary for the synthesis of PGF2α are low.  The low concentration of receptors 
effectively interrupts the ability of enough oxytocin to bind and stimulate PGF2α 
secretion (Boerboom et al., 2004).   
 The development of oxytocin receptors and the ability of the endometrium to then 
release PGF2α in response to oxytocin is the first key aspect of luteolysis in the mare.  
The second important aspect of luteolysis is the upregulation of enzymes that play a role 
in the synthesis of PGF2α (Boerboom et al., 2004).  Prostaglandins are produced in 
response to a wide variety of stimuli, including oxytocin binding to its receptor, which 
ultimately results in the activation of phospholipase A2 (PLA2) that results in the 
liberation of arachidonic acid (AA) from membrane phospholipids (Boerboom et al., 
2004).  This phenomenon generates the substrate necessary for PGF2α synthesis (Keith et 
al., 2013).    
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 Oxytocin receptor activation also plays a role in the activation of mitogen-
activated protein kinase, which is important in the regulation of cyclooxygenase gene 
expression (Molnar et al., 1999; Soloff et al., 2000).  These cyclooxygenase enzymes are 
rate-limiting enzymes for prostaglandin synthesis and occur in two forms.  
Cyclooxygenase 1 (COX-1) and cyclooxygenase-2 (COX-2) both work downstream of 
PLA2 and convert arachidonic acid to prostaglandin G2 and H2. Prostaglandin H2 can then 
be converted into PGF2α by prostaglandin F synthase (PGFS) in the uterus (Keith et al., 
2013).   
 COX-2 appears to be more heavily involved in the mechanisms of luteolysis and 
maternal recognition of pregnancy than COX-1.  In both cows and sheep, COX-2 
expression was found in late diestrus, occurring around the time of luteolysis, however, 
COX-1 was minimally found in sheep and undetectable in cows (Charpigny et al., 1997; 
Arosh et al., 2002) While COX-2 is strongly expressed around the time of luteolysis, this 
phenomenon does not occur during pregnancy in the mare.  This suggests that the equine 
conceptus somehow blocks the synthesis of PGF2α in the endometrium by repressing 
COX-2 expression.  It appears that the prevention of luteolysis depends on the inhibition 
of COX-2 expression and the decrease of oxytocin receptors (Boerboom et al., 2004).   
 Understanding the complex role of oxytocin in equine luteolysis and pregnancy is 
important for the use of oxytocin in preventing luteolysis.  Preventing the termination of 
the CL through understanding the interactions of oxytocin is key for the use of oxytocin 





Prolonged Luteal Function 
 
 The condition of prolonged luteal function can occur spontaneously in the mare, 
creating a difficult challenge in mare reproduction.  As previously reviewed, the 
luteolytic event is characterized by the structural and functional demise of the CL.  At 
times, and for many reasons, the CL can spontaneously remain present on the ovary 
beyond the expected time of luteolysis in a nonpregnant mare.  This occurrence is 
referred to by many different terms, but all are similar in referring to persistence of the 
CL on the ovary.   
 Prolonged, or persistent luteal activity can occur in mares during approximately 8-
10% of interovulatory intervals during peak ovulatory season.  This number increases 
significantly during the fall transition period, rising to 25% (King et al., 2010).  The 
occurrence of persistent luteal function has been associated with a few different uterine 
pathologies such as pyometra, as well as with early embryonic loss (Hughes et al., 1979; 
Bergfelt et al., 1992).  There are instances where the CL is prolonged or persistent 
without any obvious reason and, in that situation, is typically referred to as spontaneous 
or idiopathic prolonged CL function (Stabenfeldt et al., 1974; Ginther, 1990).   
 There are a few situations that are thought to be the source of spontaneously 
prolonged CL function including the failure of the CL to respond to PGF2α, failure of the 
PGF2α to travel to the CL, and failure of the uterus to synthesize PGF2α (Ginther, 1990).  
Mares are thought to have prolonged CL function when their progesterone concentrations 
are greater than 1.0 ng/mL for at approximately 60 days, although the duration can range 
from 35-95 days (Santos et al., 2015).   
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 While the development of spontaneously prolonged CL function can be 
inconvenient and frustrating in equine reproductive biology, it does also serve as a basis 
of understanding for prolonging CL function intentionally for the purpose of estrus 
suppression.  This method would be an effort to use the CL and subsequent progesterone 
levels to keep the mare out of normal estrus, and allow the naturally secreted 
progesterone to eliminate behaviors associated with estrus.  Prolonging CL function is an 
excellent option for estrus suppression in equine performance settings and will be 
discussed in detail later in this review.   
General Methods of Estrus Suppression 
 
 Prolonging CL function is not the only method of estrus suppression that is used 
within the equine industry.  For the purpose of this review, multiple other methods will 
be outlined in order to give an overview of the advantages and disadvantages of each.   
 Previously in this review, the issue of mare performance and behaviors related to 
the estrous cycle was addressed.  The common complaint of those involved in the 
industry has been a factor in the research efforts for estrus suppression.  For years, 
different methods have been used with varying levels of success.  Mares are used often in 
the performance industry and the control of their estrous cycles and subsequent behaviors 
is warranted.  As stated previously, the effect of the estrous cycle, particularly during the 
state of estrus, on the performance of mares can be variable, making the showing and use 
of these animals difficult or inconvenient.   
 Over the years, the development of different methods of suppressing estrus has 
grown and there are many different avenues to achieve the desired effects.  Some 
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methods are more effective than others and have led to some techniques being less 
frequently used and other, newer techniques developing.  Overall, there is a growing need 
for the effective control of estrus that will benefit the equine performance industry.  
Much research has been dedicated to this topic and it is the purpose of this review to 
outline and describe the various methods that are available to suppress estrus in addition 
to their effectiveness and safety.   
 The methods of estrus suppression that exist can be broken down into a few 
different categories.  Most of these methods fall under the categories of hormonal, 
surgical, immunologic, and others methods.  It is important to note that mares are unique 
animals, differing in many ways from other domestic animals.  Previously, this review 
has pointed out differences in anatomy and physiology that vary greatly from other 
domestic species pertaining to reproduction.  Some methods of synchronization or 
suppression of estrus used in other species are not necessarily effective in the equine 
species.  The following methods to be reviewed represent the general body of research 
and methods related to estrus suppression in mares.  
 




 The use of exogenous progesterone/progestins has been widely used as a method 
of estrus suppression.  Staring in the 1960s, Loy et al., (1966) found that intramuscular 
injection of 0.2 mg/kg of progesterone oil was effective in suppressing signs of estrus in 
mares (Loy and Swan, 1966).  Although this was found to be effective and progesterone 
in oil is available from pharmacies, it’s need for daily administration and long-term 
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injections proved limiting.  Progesterone has historically been associated with tissue 
reactions at the injection site, making this method undesirable to owners and creating 
horses with needle aversions (Pryor and Tibary, 2005).  One alternative that developed 
was the use of another compounded formulation of progesterone, this time a long-acting 
formulation of 1.5 grams (g), which maintained blood progesterone levels above 1.0 
ng/mL for approximately 10 days (Vanderwall et al., 2007a).  Although this compounded 
formula allowed for more time between injections, the potential for soreness at the 
injection site was again a limitation for use in performance horses.  The long-acting 
formulation is also not approved by the FDA, which poses risk to veterinarians and 
clients. 
 Perhaps the most commonly used and successful method of administration of 
exogenous progesterone/progestins is altrenogest, an orally active synthetic progestin.  It 
is FDA approved, and considered the “gold standard” as far as methods used to suppress 
estrus in mares.  The typical dose is 0.044 mg/kg daily, orally and has been proven to be 
effective in suppressing estrus.  The altrenogest is most widely known as ReguMate 
(Intervet/Merck Animal Health, Summit, NJ), and while it is proven to be effective, one 
study found that 76.6% of veterinarians participated in administering altrenogest to 
performance mares with an observed decline in performance related to estrus, but only 
44% of owners reported it to be successful (80% improvement) (Jorgensen et al., 1996).  
This can be related to the ability of mares to maintain follicular activity and possible 
ovulation.  As a result, mares that display preovulatory pain related to follicles and 
ovulation may show continued discomfort despite treatment with altrenogest.   Other 
disadvantages exist such as the need for daily administration, expense, and the added 
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safety concern of personnel during handling and administration (Squires et al., 1979; 
Vanderwall, 2012).  Alternatively, it has been reported that IM administration of 
altrenogest in a compounded formula containing 225 mg or 450 mg of altrenogest with a 
sustained-release administration effectively blocked estrous behavior for 12 and 15 days, 
respectively.  Administration of the 500 mg of altrenogest suppressed estrous behavior 
for approximately 30 days (Storer et al., 2009).  Although injectable altrenogest appears 
effective, it is not an FDA approved method and the compounded products can vary in 
potency and stability.  This poses difficulties with variable results as well as a problem 
for veterinarians who should use FDA approved products (Vanderwall, 2013).  In 
addition to these disadvantages, another issue exists.  Altrenogest is a 17α-allyl derivative 
of trenbolone, an anabolic steroid similar to testosterone.  Because of the similarities to 
anabolic steroids, the use of altrenogest in performance horses is under increased scrutiny 
and is considered a doping agent in some countries (Pryor and Tibary, 2005).  However, 
one study showed that mares treated with altrenogest for the recommended period of 
eight weeks did not display any characteristics of anabolic steroids in horses such as 
dominance, body mass, or body condition scores compared to control mares (Hodgson et 
al., 2005).  Other restrictions related to the administration of altrenogest also exist.  Long-
acting progesterone is not permitted by the British Jockey club, the Swedish Trotting 
Association, and the International Federation for Equine Sports.  In addition to these 
restrictions, the use of oral altrenogest is also prohibited for competition horses (Hedberg 
et al., 2006). 
 There have been reports of the use of other synthetic progestins for estrus 
suppression in mares, however, none have been found to stand up to rigorous testing and 
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still be deemed effective (Vanderwall et al., 2012b).  Reportedly, other synthetic 
progestins are rather ineffective, so altrenogest remains the most widely used and 
successful method of administering exogenous progesterone/progestins, however because 
of the many drawbacks, an effective alternative is needed.   
Pregnancy  
 
 Pregnancy is another means of estrus suppression that has been found to be 
effective.  This takes advantage of the natural role of the conceptus to effectively block 
luteolysis, subsequently maintaining CL function and continuing secretion of 
progesterone.  In a study by Lefranc and Allen, the establishment of pregnancy, followed 
by the manual transrectal rupture of the conceptus between days 16 and 22 of gestation 
resulted in 10 of 11 mares (91%) displaying prolonged CL function for at least 60 days.  
These mares did not display estrous behavior during that time (Lefranc and Allen, 2004).  
A pregnant mare can also be aborted between days 50-60 of gestation and have elevated 
progesterone levels for 120 days or more. This is much more difficult than aborting the 
fetus at an earlier time.  Aborting later, during those particular days of the pregnancy is 
effective as a result of the endometrial cups that have developed by that period and the 
mare will not return to estrus for approximately 60 days.  It is important to note that a 
small amount of mares will also display behavioral signs during pregnancy (Nie, 2007).  
While pregnancy is an effective method of suspending cyclicity, there are some obvious 
disadvantages that may prove undesirable for many horse owners.  Factors such as the 
cost involved with establishing pregnancy, especially if a foal is undesired, and the ethics 
involved with terminating a healthy conceptus may be unacceptable to horse owners 





 A variety of implants containing progestins, which are labeled for use in other 
species, have been used experimentally in mares in an effort to suppress estrus.  
Progesterone delivered vaginally through the use of a Controlled Intravaginal Drug 
Release (CIDR) has also been used, however, it was not considered to be a useful 
method in performance horses (Pryor and Tibary, 2005).  
 The use of bovine hormonal implants has also been examined for use in mares.  In 
cattle, the implants are used as weight gain promoters.  These implants come in various 
forms such as Synovex-C ® (Fort Dodge Animal Health, Overland Park, KS) which 
contains 100 mg of progesterone and 10 mg of estradiol benzoate, or Synovex-S ®, 
(containing 200 mg of progesterone and 20 mg of estradiol benzoate).  The use of these 
implants has been frequently talked about and used in equine medicine, and in 1996, a 
survey reported that the use of these implants were the second most commonly used 
method for estrus suppression.   Almost 71% of owners and trainers felt that it was 
effective, however, the scientific data shows that the use of these implants is not effective 
in suppressing estrus in mares (Jorgensen et al., 1996).  The doses of these implants have 
even been used in large numbers (up to 80 implants) rather than the labeled dose of eight 
pellets.  The pellets have been implanted in various regions of the mare’s body including 
the pectoral region, under the mane, and in the vulva.  Scar tissue and inflammation can 
develop at these sites (Nie, 2007).  The unsuccessful nature of using these implants is due 
to the lack of absorption of progesterone in sufficient quantity (McCue et al., 1997).   
 Other implants have been studied, such as an implantable norgestomet (Crestar, 
Intervet Australia, Bendigo East Victoria, Australia), a pellet that is marketed for estrus 
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suppression in mares, and Levonorgestrel (Norplant, Wyeth, Collegeville, PA), which is 
an implantable progestin used as a contraceptive in women.  There is la lack of evidence 
of valid information regarding dose, frequency, response, or safety of these products.  
Another implant that has been examined is Zeranol (Ralgro, Schering-Plough, 
Kenilworth, NJ), which is an anabolic agent used for growth stimulation in cattle.  
Veterinarians report minimal use for estrus suppression in mares and those that have 
administered it used doses ranging from 1-3 pellets (12-36 mg) per mare.  All reports 
available indicate that Zeranol is ineffective for estrus suppression in mares (Nie, 2007).   
 The use of deslorelin acetate in the form of an implant known as Ovuplant (Fort 
Dodge) has also been used.  Deslorelin Acetate is an analogue of GnRH and has been 
found to induce ovulation in mares when a follicle of greater than 35 mm in diameter is 
present (McKinnon et al., 1993; Mumford et al., 1995). One study showed that upon 
implanting a double dose (two 2.1 Ovuplant implants) of deslorelin acetate, most mares 
displayed suppressed follicular activity for at least 30 days (McCue et al., 2000).  In order 
to achieve complete arrest of ovarian activity, Johnson et al., reported that three 
deslorelin implants were used, however, these results were not completely reliable.  
When mares received three implants, the interovulatory period was extended (36.8 days) 
as compared to mares with a single implant (22 days). While it is possible that some 
mares are sensitive to down regulation, complete ovarian inactivity was not achieved, 
even with three implants (Johnson et al., 2002; Johnson et al., 2003). 
 It appears that the use of various implants is useful in some situations, with 
different products being more successful than others. The need for a method of estrus 





 There appears to be conflicting reports regarding the effectiveness of 
glucocorticoids on suppressing estrus in mares.  One group reported that administration 
of dexamethasone (30 mg/day) to mares that are on day 10 of the cycle (post-ovulation) 
suppressed estrus in seven of eight mares compared to control mares (Asa and Ginther, 
1982).  The controversy lies in the contrasting report of McKinnon et al., (1997) who 
were unable to suppress or prevent follicular development of the estrous cycle when 
administering dexamethasome in late estrus.  Although there are reports of effective use 
of dexamethasone, it is thought that there are potential effects of long-term use that 
warrant caution.  Veterinarians surveyed reported no use of glucocorticoids to suppress 
estrus (Nie, 2007).   
Medroxyprogesterone Acetate 
 
 The use of other progestins has been examined such as megestrol acetate, 
hydroxyprogesterone caproate, and hydroxyprogesterone hexanoate. These progestins 
failed to be useful to help maintain pregnancy in the mare, most likely because of the 
inability to bind to the progesterone receptor in horses.   One long-acting progestin that 
has also been examined for equine use is medroxyprogesterone acetate (MPA) better 
known in human medicine as Depo-Provera (Pfizer).  It is highly successful as a human 
contraceptive given every 3 months via injection.  It has been found to be effective in 
suppressing estrus in queens and bitches, however, it is associated with a high rate of 
undesirable side effects (Kutzler and Wood, 2006).  The use of MPA in mares has 
occurred, but results and effectiveness vary.  Gee et al., (2009) found that administration 
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of compounded MPA starting on day 7 with 1,600 mg MPA intramuscularly and 
continuing with 400 mg on days 14, 21, 28, 35, and 42 had no effect on estrous behavior, 
nor follicular development, serum progesterone or LH concentrations.   
Induction of a Late-Diestrus Ovulation  
 
 Mares, as mentioned earlier, have several differences from females of others 
species in various ways.  One such difference unique to mares is the ability to ovulate 
during diestrus, despite high progesterone concentrations.   This phenomenon can happen 
in approximately 20% of Thoroughbreds and Quarter Horses during the luteal phase, 
however, in ponies, the frequency is very low (Wesson and Ginther, 1981; Hughes et al., 
1985).  Spontaneous diestrus ovulations can occur between one to four days prior to 
luteolysis and may cause a prolonged luteal phase.  This is due to the immature CL being 
refractory to prostaglandin (Douglas and Ginther, 1975b).  Inducing a late-diestrus 
ovulation using human chorionic gonadotropin (hCG) has been explored.  Hedberg et al. 
(2006) conducted a study during which five treatment mares and four control mares were 
monitored starting on day 8 post-ovulation.  Using transrectal palpation and ultrasound, 
mares were examined until a diestrus follicle greater than 30 mm was found.  Treatment 
of saline or 3000 units of hCG intramuscularly followed.  The mares continued to be 
monitored and at the conclusion of the study, three of the four mares that developed a 30 
mm follicle and received hCG treatment, ovulated and displayed prolonged luteal phases 
lasting 58 to 82 days after treatment.   
 This method appears successful, however, it is important to note that one mare 
never developed a large enough follicle to be treated with hCG.  Also, of the mares that 
were treated, five of the nine required multiple estrous cycles to develop a follicle large 
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enough to be treated (Hedberg et al., 2006).  The advantages of this method are 
outweighed by the cost and effort made to frequently check the mares to determine 
eligibility for treatment, as well as the fact that some mares may take multiple cycles to 
develop a suitable follicle or one at all.  This does not provide owners with a method that 
allows for estrus suppression in a timely manner and further exploration for a safe, 
reliable, and effective method are needed. 
Intrauterine Infusion of Plant Oils 
 
 Intrauterine infusion of plant oils as a method of suppressing estrus is another 
avenue that has been explored.  A study was published by Wilsher and Allen (2011), 
demonstrating that infusion of 10 mg of estradiol in 1 mL of fractionated coconut oil was 
effective.  Administration on day 6, 8, 10, 12, or 14 post-ovulation resulted in prolonged 
CL function in 25%, 75%, 92%, 83%, and 50% of treated mares, respectively.  Further 
investigation demonstrated that estradiol was not needed for prolonged CL function 
because 1 mL fractionated coconut or peanut oil, neither with estradiol, on day 10 
resulted in 92% of mares displaying prolonged CL function.  It has been hypothesized 
that the effectiveness of infusion of plant oils is based on the fatty acid milieus present in 
the oils of both plants and the role of modulating synthesis and/or secretion of PGF2α 
near the time of luteolysis, thus resulting in prolonged CL function.  The infusion of plant 
oils appears to be an effective method of suppressing estrus, however, more research on 







 Placement of an intrauterine device to prolong function of the CL is a common 
method of estrus suppression.  Nie et al., (2003) found that placement of a 25 or 35 mm 
glass ball into the uterus, at the time of ovulation, prolonged CL function in seven of 18 
mares (39%) that retained the glass ball.  Six of 12 mares quickly expelled the 25 mm 
glass ball after insertion.  In the mares that developed prolonged CL function for 
approximately 90 days, blood progesterone levels did not decline below 1.0 ng/mL and 
no estrous behavior was exhibited. In the control group, four of 32 mares (13%) 
displayed spontaneously prolonged luteal function, a phenomenon that has been 
discussed previously.  
 This method appears effective in blocking estrus for an extended time, however in 
11 mares that retained the glass ball, extended CL function never developed and the 
mares continued to cycle normally.  In addition, three of the seven mares that received a 
glass ball underwent two or three normal estrous cycles prior to displaying prolonged CL 
function.  Although the use of a glass ball does work, it’s lack of consistency creates a 
low rate of success.  On a “per cycle” basis, the proportion of mares with prolonged CL 
function was only 7/62 cycles (11%) compared to the mares in the control group with 
spontaneously prolonged CL function, which was 4/50 cycles (8%) (Nie et al., 2003), 
which was not significantly different.   
 It is plausible the mechanism by which a glass ball facilitates prolonged CL 
function is similar to the action of an embryo to prevent luteolysis.  The “embryo 
mimicking” effect of the presence of the glass ball may interrupt the up-regulation of 
endometrial gene expression of the enzyme COX-2, which as discussed previously, plays 
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an important role in the synthesis and secretion of PGF2α (Boerboom et al., 2004).  In a 
study by Rivera del Alamo et al., (2008) the use of an intrauterine device induced 
prolonged CL function in 75% of the mares in the study.  The higher success rate is could 
be attributed to the fact that no uterine treatments were performed after the insertion of 
the device, as opposed to Nie et al. (2003) who infused the uterus with 1 g of ticarcillin 
disodium in a 35-mL volume, and the fact that Rivera del Alamo, as opposed to Nie, did 
not use cloprostenol, which can decrease progesterone levels.  Other differences in the 
studies related to the size, material, and weight of the devices.  The glass balls used by 
Nie et al. (2003) had diameters of 25 to 35 mm, making them larger and heavier than the 
plastic balls used by Rivera del Alamo et al. which were water filled polypropylene balls 
measuring 20 mm in diameter.  It was hypothesized that a lighter device might move 
within the uterus more and be more effective in inducing prolonged luteal function, 
however, there was no significant difference in mobility found.  It was concluded, similar 
to Nie et al., that the “embryo-mimicking” effect of the intrauterine device prevents the 
upregulation of COX-2 (Rivera del Alamo et al., 2008). 
 A veterinarian must perform the placement and removal of an intrauterine glass 
ball.  The glass ball is autoclaved for sterilization prior to placement.  The mare must be 
in late estrus or close to ovulation, with a relaxed cervix for the glass ball to be manually 
placed in the uterus by the veterinarian in sterile procedure.  The marble is placed 
vaginally and pushed through the cervix, followed by location of the glass ball per rectum 
and pushed forward into the uterine body.  Removal involves the mare to be in peak 
estrus, and the glass ball is manipulated toward the cervix then removed (Nie, 2007).   
 
34 
 In the same study by Nie et al., (2003) the use of intrauterine glass balls was 
deemed safe.  In more recent years, it has been reported that spontaneous fragmentation 
as well as irritation, colic, and pyometra has occurred (Klabnick-Bradford, 2013; 
Freeman, 2015).  Plastic has been used in an effort to reduce this complication, however, 
regardless of material used, some mares retain the devices long enough that the presence 
of an intrauterine device may not be disclosed when the mare is sold, and anecdotal 
reports of mares becoming pregnant regardless of the device and aborting is also a 
concern (Vanderwall, 2013).   
 Because of the variability in effectiveness and the potential for serious 
complications, a method with increased reliability and safety, as well as easily reversed is 





 As previously reviewed, GnRH plays a pivotal role in equine reproduction.  
Ovarian activity is heavily influenced by gonadotropin secretion, which is regulated by 
GnRH.  The immunization of horses against GnRH has been researched for several years 
and numerous studies have taken place to determine the effectiveness of this method.  
Vaccination against GnRH results in the induction of anti-GnRH antibody and these 
antibodies bind to endogenous GnRH preventing it from stimulating gonadotropin 
secretion from the anterior pituitary gland.  The binding in this location prevents the 
stimulus to gonadotropin secretion and decreases ovarian activity (Pryor and Tibary, 
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2005).  The use of a GnRH vaccine has been studied in multiple species, from elephants 
to humans, with a wide variety of objectives.   
 The use of the vaccine in wild animals has been shown to be an effective method 
of population control (D'Occhio, 1993; Fayrer-Hosken et al., 2000).  Applications for 
human use includes GnRH vaccine to decrease testosterone levels for treatment of 
prostate cancer (Simms et al., 2000).  Aside from these uses, the application of the 
vaccine in farm animals is the most relevant to this review.  It has been shown to be an 
alternative to surgical castration and is efficacious in decreasing sexual and aggressive 
behavior in cattle, as well as the prevention of pregnancy in pigs (Esbenshade and Britt, 
1985; Prendiville et al., 1995; Thompson, 2000).   
 In horses, the use of GnRH vaccine started as an alternative to castration but soon 
evolved into use in mares.  In the first studies, ovarian activity and estrous behavior were 
not monitored (Garza et al., 1986; Safir et al., 1987).  The vaccine was administered with 
a primary goal of investigating the effects of GnRH vaccination and the relationship with 
gonadotropin secretion.  At the cessation of the studies, the mares were either 
ovariectomized or the study was terminated and mares were not tracked for normal 
cyclicity.  Thus, no information was gathered about the safety of the immunization 
regarding future reproduction.  Later studies found the same treatment effective in six 2-
year-old fillies and data was collected regarding behavior as well.  Both ovarian function 
and estrous behavior were suppressed and the fillies returned to normal reproductive 
function (Tshewang et al., 1997), however, in mature mares, there was greater variation 
in these results, with anestrus lasting up to 15 months in two of three mares vaccinated.  
The study also reported that mares with totally inactive ovaries continued to show estrus 
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signs with varied duration and variability (Dalin et al., 2002).   This is related to the 
occurrence of “paradoxical estrus” in mares, which is due to the fact that hormone driven 
behavior can originate from locations other than the ovaries, such as the adrenal glands.  
This phenomenon is also a factor in the practice of ovariectomy, which is discussed 
below.   
 In a study by Imboden et al. (2006) the primary goal was to investigate the results 
of immunization of GnRH and effects on the reproductive tract.  The mares were 
administered Improvac ® (CSL Limited, Australia), which has been successfully used to 
control boar taint in pigs.  All nine treatment mares showed an immediate response to the 
first vaccine and peak response after the booster injection.  Titers reached high levels and 
then slowly declined until 100 weeks following the first vaccination, however, as 
demonstrated by previous studies, titer can be independent of degree of ovarian 
suppression and variable per individual.  In spite of suppression of ovarian function, four 
mares displayed sporadic estrous behavior and one mare continuously displayed those 
behaviors.  In addition to variation in titer, resumption of normal cyclicity was variable 
and adverse effects such as tissue swelling at the injection site, lameness, and fever were 
also reported.  
 More recently, another GnRH vaccine (EquityTM oestrus control: CSL Animal 
Health, Victoria, Australia) was licensed for use in mares in Australia, specifically for 
control of estrus.  The protocol involves four intramuscular injections of vaccine to the 
pectoralis region of muscle.  The treatments are staggered with the first injection 
administered 10 days post-ovulation, the second injection 20 following the first, and the 
third 20 days following that.  The fourth injection is administered 30 days after the third 
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injection.  Immunization resulted in a response of GnRH antibodies in all mares, 
however, individual variability in response once again occurred.  Also, because the 
GnRH is mixed with Equimune ®, which has a strong effect at the injection site, 
inflammation and irritation can occur (Pryor and Tibary, 2005) 
 The use of GnRH vaccine is somewhat effective and eventually reversible, 
however, the length of time needed for resumption of cyclicity does not provide a method 
that is easily reversible for breeding purposes.  The failure of some mares to return to 
cyclicity is concerning as well.  Most importantly, because of the nature of the adrenal 
glands, merely suppressing ovarian activity does not always prevent unwanted estrous 
behavior and thus the vaccination against GnRH does not provide a method that is as 






 Ovariectomy, or “spaying” a mare is considered a last resort for behavioral 
modification or estrus suppression.  This procedure involves the removal of the ovaries 
through various methods including a ventral abdominal incision or flank laparotomy, 
laparoscopy, or colpotomy (Ross, 1991; Hooper et al., 1993; Rodgerson et al., 2001).  
This method is a permanent procedure, thus eliminating any future reproductive potential.   
 A common misconception regarding ovariectomy is the complete removal of 
unwanted behavior or that mare’s behavior will be similar to her behavior after 
exogenous hormones (McCue, 2003).  Again, mares differ from other animals due to the 
fact that not all of their hormone driven behavior originates from ovarian derived 
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estrogen.  Mares can display “paradoxical” estrous behavior even during seasonally 
anovulatory periods as well as after ovariectomy.  This phenomenon occurs as a result of 
hormone secretion from the adrenal cortex (Asa et al., 1980).  This is an important factor 
to consider when evaluating ovariectomy.   
 In a study by Jorgensen et al. (1996), they found that ovariectomy was utilized by 
44% of respondents, and 60.5% of respondents reported an improvement of behavior in 
80% or more of treated mares.  Forty-five percent of owners and trainers reported 80% or 
better improvement in athletic performance in ovariectomized mares.  These results are 
much better than scientific reports that show 30% or more of ovariectomized mares 
continue to display some form of behavioral estrus.  It is important to note that low 
progesterone is all that is needed for a mare to display estrus and estrogen intensifies 
estrus, but is not always needed.  Thus, if a mare’s behavioral issues are truly associated 
with estrus, ovariectomy could have the opposite effect and make the behavior of the 
mare worse (Pryor and Tibary, 2005).   
 The best option for determining if ovariectomy should be performed is the 
observation of behavior during the winter anestrus period when mare’s hormone 
production and ovarian function are very minimal.  Observations during this period could 
allow options to be carefully weighed and the origin of the mare’s behavior to be better 





 Thus far, this review has covered many of the general methods of estrus 
suppression.  These have all fallen into the categories of hormonal, surgical, and 
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immunological methods.  Most of the methods reviewed in the hormonal category are 
methods used specifically to prolong the function of the CL on the ovary, thus the natural 
secretion of progesterone occurs, suppressing estrus naturally.  The methods already 
discussed that fall in the category of prolonged CL function include the use of an 
intrauterine glass ball, pregnancy, infusion of plant oils, and induction of a late diestrus 
ovulation.  The advantages and disadvantages have been discussed, however, there is 
need for another method of prolonged CL function that is safe, reliable, effective, and 
easily reversible.   
 The administration of exogenous oxytocin during the diestrus period is a 
promising alternative method of blocking luteolysis in order to prolong the function of 
the CL.  As discussed previously, endogenous oxytocin secretion plays an important role 
in luteolysis, regulating the secretion of PGF2α from the endometrium during luteolysis 
in mares (Vanderwall et al., 1998; Shand et al., 2000).  Research has discovered that 
administration of exogenous oxytocin to mares near the time of luteolysis (days 11-15 
after ovulation) induces the onset of PGF2α secretion, however, if oxytocin is 
administered prior to day 10 post-ovulation, the opposite effect occurs and PGF2α is not 
secreted, luteolysis is disrupted, and the CL remains intact for a prolonged period of time 
(Betteridge et al., 1985; Goff et al., 1987; Starbuck et al., 1998).  Further research of 
oxytocin occurred with the continuous infusion of oxytocin using an osmotic minipump 
inserted subcutaneously into the mare.  The infusion of 5 µl h-1 went from days 8-20 post-
ovulation and resulted in prolonged diestrus in four out of five mares versus all four 
control mares that were administered saline and underwent luteolysis at the expected 
time.  When the infusion via the minipump began on day 10, prolonged diestrus occurred 
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in three out of five mares and in the two mares without prolonged CL function, luteolysis 
was induced immediately.  Luteolysis occurred at the expected time in the four control 
mares infused with saline (Stout et al., 1999). This method worked, however, the 
continuous nature of treatment was impractical as a long-term method for the suppression 
of estrus.   
 In an effort to avoid continuous infusion, Vanderwall et al. (2007b) conducted a 
study in which six mares were treated with 60 units (3 mL) of oxytocin, IM, twice daily 
on days 7 to 14 after ovulation.  Six control mares were administered the same volume of 
saline.  This proved effective; with prolonged CL function being observed through day 30 
in all the treated mares whereas all control mares underwent luteolysis by day 16 of their 
cycle.  It was then hypothesized that a once-daily injection of oxytocin would be as 
effective as the twice-daily protocol.  Once-daily injections would greatly simplify the 
protocol for veterinarians and owners.   In a subsequent study by Vanderwall et al., 
(2012b) the same 60-unit dose of oxytocin was administered twice daily to seven mares 
and once daily to eight mares.  The occurrence of prolonged CL function was five of 
seven mares (71%), five of eight mares (63%) respectively, while one of seven (14%) of 
control mares displayed spontaneously prolonged CL function.  No difference (P > 0.05) 
was found in the proportion of mares with prolonged CL function between the once daily 
and twice daily oxytocin treatments.  It was concluded that the administration of oxytocin 
could be reduced from twice to once daily and still remain effective.   
 In another study, Vanderwall et al. (2012a) again designed a study around the use 
of oxytocin to suppress estrus.  In this particular protocol, the once daily administration 
of 60 units of oxytocin was given on days 7 to 14 post-ovulation.  The objective was to 
 
41 
monitor duration of CL function and estrous behavior in mares for 90 days after 
administration. Two of the nine control mares (22%) had spontaneously prolonged CL 
function whereas six of the nine oxytocin-treated (67%) also had prolonged CL function 
(P = 0.08).   The control mares that displayed spontaneous prolonged CL function had a 
mean duration of CL function of 78 days.  The six treatment mares had a mean duration 
of CL function of 69 days.  The mares in the control group and one of the mares in the 
treatment group with prolonged CL function did not display estrous behavior during the 
time their plasma progesterone remained above 1.0 ng/mL.  Interestingly, the remaining 
five treatment mares with prolonged CL function did display weak estrus occasionally 
during a period of elevated progesterone.  It was concluded that the oxytocin treatment 
works for approximately two months in two thirds of treated mares.   
 Other groups have tried the oxytocin protocol with altered dose and route of 
administration, as well as duration of treatment.  Gee et al. (2012) reported that five of six 
mares (83%) treated with 10 units of oxytocin intravenously (IV) once daily also on days 
7-14 displayed prolonged CL function compared to one of the six (17%) mares treated 
with 10 units intramuscularly, and two of the (33%) mares treated with saline 
intramuscularly.  This data combined with the previously discussed data indicates that the 
dose of 10 units of oxytocin administered intramuscularly does not prolong CL function 
and the threshold for an intramuscular dose to disrupt luteolysis is between 10 and 60 
units of oxytocin.  In all of the mares with prolonged CL function, estrous behavior was 
inhibited, which demonstrates the effectiveness of administration of oxytocin for estrus 
suppression.  Discovering the threshold for intramuscular injections is important for 
keeping the protocol user friendly for horse owners.   
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 In a 2013 study by Keith et al., three different durations of oxytocin treatment 
were examined.  Sixty units of oxytocin were administered intramuscularly on day 8 and 
then the three different durations of treatment (2, 4, or 6 days).  Administration of 
oxytocin on days 8 to 10, 8 to 12, an 8 to 14 resulted in prolonged CL function in three of 
seven (43%), four of seven (57%), and six of seven (86%) of mares, respectively.  None 
of the control mares displayed any prolonged luteal function.  These results showed that 
the proportion of mares with prolonged CL function was increased as treatment days 
increased, thus confirming that the most effective treatment time for oxytocin is from 
days 8 to 14, or the expected time of luteolysis. 
 In one study, the synthetic oxytocin analog known as carbetocin was administered 
to mares on days 7 to 14 post-ovulation and compared to another group of oxytocin 
treated mares for the same duration.  The oxytocin treated mares were administered 60 
units of oxytocin intramuscularly, once daily.  The carbetocin treated mares were 
administered the equivalent dose of 1.19 mg carbetocin intramuscularly, once daily on 
days 7 to 14.  The administration of oxytocin increased the inter-ovulatory interval (P < 
0.01) while the carbetocin decreased the inter-ovulatory interval (P>0.01) and essential 
“short-cycled” the mares.  It was concluded that the use of carbetocin in this dose, 
treatment, and schedule was not effective in prolonging CL function (Bare et al., 2013). 
 Previously in this review, the role of oxytocin in luteolysis was addressed.  It is 
known that the ability of the endometrium to secrete PGF2α in response to either 
exogenous or endogenous oxytocin increases between days 10-15 after ovulation.  This 
sensitivity is related to the rise of oxytocin receptors as well as enzymes needed for 
PGF2α synthesis.  Before day 10, these same receptors and enzymes are low which plays 
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a role in the ability of oxytocin to influence PGF2α secretion.   In an effort to understand 
the mechanism of action of exogenous oxytocin, Vanderwall et al. (2012b) tested the 
hypothesis that the effectiveness of the administration of oxytocin on days 7 to 14 of the 
estrous cycle was effective in preventing luteolysis by inhibiting the rise of endometrial 
oxytocin receptor concentration.  It was found that no difference in endometrial oxytocin 
receptor concentration existed between treatment and control mares, thus further research 
was needed to determine the actual mechanism of action.  In 2013, Keith et al. published 
a study examining the same hypothesis, however, they were successful in determining 
why the oxytocin protocol was effective.  It was found that oxytocin treatment suppresses 
PGF2α secretion by preventing the upregulation of the gene expression of COX-2 in the 
endometrium, as previously mentioned in this review.  
 The body of research on the topic of administration of exogenous oxytocin to 
suppress estrus in mares is convincing and supports the use of 60 units of oxytocin on 
days 7 or 8, to 14 post-ovulation and the subsequent disruption of luteolysis.  Numerous 
studies by Vanderwall (2013) have shown the progression of frequency, duration, and 
mechanism of oxytocin treatments and their effect on prolonging the CL.  The 
administration of exogenous oxytocin and its ability to prolong CL function with the 
release of progesterone naturally is advantageous to veterinarians, horse owners, and 
trainers.   
 The largest disadvantage to the current oxytocin protocol is the need for detection 
of day 0 or day of ovulation in order to then begin the treatments on day 7 of the mare’s 
cycle.  Detecting ovulation must be done by a veterinarian via transrectal palpation and 
ultrasound.  Multiple trips to the veterinarian in order to establish ovulation are usually 
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needed, and the costs and effort incurred with such visits can be a disadvantage.  In an 
effort to address this issue, we hypothesized that by extending the duration of oxytocin 
administration, treatment could be initiated at any point during the estrous cycle (i.e., 
without knowing the day of ovulation) and still effectively prolong CL function.  
Therefore, the objective of this study was to determine if treating mares with oxytocin 
daily for 29 days would result in prolonged CL function.   
 
MATERIALS AND METHODS 
Animals 
 
This study was conducted in the Northern Hemisphere under natural photoperiod 
using 17 Quarter Horse-type mares that were between 2 and 17 years old and weighed 
300 to 500 kg.  All animal procedures were approved and conducted following the 
guidelines of the Utah State University Institutional Animal Care and Use Committee 
(IACUC).  The reproductive tract of each mare was examined with transrectal palpation 
and ultrasound in April and/or May to confirm that spontaneous seasonal ovulatory 
activity had commenced (i.e., a CL was identified).  All of the mares had ovulated by late 
May.  Prior to the study, no reproductive hormones were administered to any of the 
mares to regulate their cyclical reproductive activity (i.e., they were allowed to cycle 
spontaneously without hormonal manipulation).  After confirming spontaneous ovulatory 
activity in all of the mares, no further reproductive examinations were performed for the 









 Mares were randomly assigned to two groups: 1) saline-treated control (n=8) and 
2) oxytocin-treated (n=9).    Prior to initiating treatment, 10 cc of jugular blood was 
collected from each mare three times weekly (M, W, F) for three weeks.  This was done 
to determine, based upon blood progesterone concentration, whether any mares had 
spontaneously prolonged CL function before treatment was initiated (i.e., blood 
progesterone remaining >1.0 ng/mL continuously throughout the pretreatment period).  
Mares that displayed evidence of spontaneously prolonged CL function during the 
pretreatment period were removed from the study.   At the end of the pretreatment period 
(day 1), control mares began receiving 3 cc of sterile saline IM once daily and the 
oxytocin-treated mares began receiving 60 units (3cc) oxytocin IM, and those treatments 
were continued through day 29.  Starting on day 1, jugular blood samples were collected 
daily for 7 days, and then three times weekly (M, W, F) for the duration of the study 
period (day 80).  Blood samples were allowed to clot at room temperature, after which 
the serum was recovered and kept frozen at -20°C until progesterone was measured.   
Mares were considered to have prolonged CL function if serum progesterone levels 





Progesterone was measured using a commercially available kit (Immulite 
Progesterone, Siemens, Malvern, PA, USA) designed for an enzyme-amplified 
chemiluminescence assay system (Immulite 1000, Diagnostic Products Corporation, Los 
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Angeles, CA, USA) and performed according to the manufacturer’s protocol.  The intra-
assay coefficient of variance was 8.6% and the inter-assay coefficient of variance was 
10.2%.  The sensitivity of the assay was 0.2 ng/mL; values below the assay sensitivity 





The proportion of mares in each group with prolonged CL function was compared 
using Fisher’s Exact Test (GraphPad Software, Inc., La Jolla, CA, 92037).  A probability 







One saline-treated control mare had blood progesterone concentrations that 
remained above 1.0 ng/mL continuously throughout the pretreatment period, indicating 
spontaneously prolonged CL function (prior to initiating treatment).  Therefore, that mare 
was removed from the study, leaving seven mares in the control group.  The remaining 
mares in both treatment groups demonstrated baseline levels of progesterone at least once 
during the pretreatment period, indicating they had undergone luteolysis during the 3-




One of seven control mares (Figure 4) and seven of nine oxytocin-treated mares 
demonstrated prolonged CL function that was initiated during the 29-day treatment 
period.  The proportion of mares with prolonged CL function was higher in the oxytocin-
treated group compared to the saline-treated group (7/9 vs. 1/7, respectively; P<0.05).   
Three of the seven oxytocin-treated mares that developed prolonged CL function initially 
underwent luteolysis within 3 to 7 days following the start of oxytocin treatment, and 
then developed prolonged CL function after the subsequent ovulation during the 
treatment period (Figure 5).  In the other four oxytocin-treated mares that developed 
prolonged CL function, progesterone remained >1.0 ng/mL throughout the treatment 
period and into the post-treatment period (Figure 5).  All mares with prolonged CL 
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function maintained elevated blood progesterone concentrations through at least day 56 
of the study.   
 
 
    





























The results of this study supported the hypothesis that extending the duration of 
oxytocin administration allows treatment to be initiated at any point during the estrous 
cycle and still effectively prolong CL function. All of the mares with prolonged CL 
function maintained blood progesterone concentrations above 1.0 ng/mL for over 50 
days, which is a sufficient concentration of progesterone to block estrous behavior (Loy 
and Swan, 1966; Hawkins et al., 1979).  One control mare (14%) developed 
spontaneously prolonged CL function (during the treatment period), which has been 
reported to occur in approximately 8 to 10% of estrous cycles during the height of the 
physiological breeding season and up to 20 to 25% of estrous cycles during the autumnal 
transition into the anovulatory season (King et al., 2010). 
In nonpregnant mares, the ability of the endometrium to secrete PGF2α in 
response to oxytocin (endogenous or exogenous) increases between days 10 and 15 post-
ovulation as a result of increasing concentrations of endometrial oxytocin receptors 
(Sharp et al., 1997; Starbuck et al., 1998) and PGF2α α synthetic enzymes  (Boerboom, et 
al., 2004).  In contrast, before day 10, endometrial oxytocin receptor concentrations and 
PGF2α synthetic enzymes are low (Sharp et al., 1997; Starbuck et al., 1998; Boerboom et 
al., 2004), thus blocking the ability of oxytocin to stimulate PGF2α secretion.  In a 
previous study by Vanderwall et al. (2012b), it was hypothesized that initiating treatment 
with oxytocin prior to day 10 post-ovulation prevented subsequent luteolysis by 
inhibiting an increase in endometrial oxytocin receptor concentration.  However, there 
was no difference in endometrial oxytocin receptor concentrations between control and 
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oxytocin-treated mares on day 15, so that hypothesis was not supported.  Subsequently, 
Keith et al. (2013) demonstrated that initiating oxytocin treatment prior to day 10 
suppresses PGF2α secretion by preventing upregulation of endometrial gene expression 
of cyclooxygenase-2, the key regulatory enzyme in PGF2α synthesis/secretion that 
otherwise would be upregulated on days 14 to 15, allowing the onset of PGF2α secretion.  
Therefore, the anti-luteolytic effect of exogenous oxytocin occurs “downstream” from its 
receptor.    
In an effort to simplify the oxytocin treatment protocol by eliminating the need 
for detection of ovulation, we extended the treatment period to 29 days and initiated 
treatment randomly during the estrous cycle.   This was done with the anticipation that 
treatment would likely be initiated in some mares on days 10 to 15, which as described 
above, would induce PGF2α secretion causing luteolysis to occur.   Therefore, the 29-day 
period of treatment was designed to ensure continued treatment of mares in which 
luteolysis was induced for a long enough period such that after they underwent luteolysis, 
they would still be receiving oxytocin on the critical days (days 7 to 14) of the following 
cycle.   As these results demonstrated, three of the seven mares that displayed prolonged 
luteal function initially underwent luteolysis and then subsequently developed prolonged 
CL function.  The other four mares in the treatment group that had prolonged CL function 
must have received oxytocin treatments beginning prior to day 10 of their cycle, since 
they did not undergo luteolysis immediately following the start of oxytocin treatment.   
In conclusion, the results of this study demonstrated the effectiveness of chronic 
oxytocin treatment; initiated randomly during the estrous cycle, for prolonging CL 





 The suppression of estrus in mares is a growing trend and is important to the 
equine industry.  Mares are frequently used and the variable behavior and performance 
related to the estrous cycle is frustrating and costly.  Over the course of the last decade, 
research has developed various methods to suppress estrus and the use of exogenous 
oxytocin appears to be effective and significant.  The 29-day oxytocin protocol addresses 
issues previously discussed regarding the growing scrutiny of administering synthetic 
progestins to performance animals and issues with safety for personnel handling 
hormones.   Another advantage of exogenous oxytocin is the easy reversal of the state of 
prolonged luteal function with a luteolytic dose of PGF2α, which will allow the mare to 
return to normal cyclicity.  The oxytocin protocol is also advantageous because of the 
low cost of materials, as opposed to synthetic progesterone/progestins.  This is of great 
advantage to the consumer, whereas orally active altrenogest can be expensive and 
needed long term.   The greatest advantage to this protocol exists in the elimination of 
frequent and expensive trips to a veterinarian.   Reducing these trips and the ease of 
administration of oxytocin in an IM dose presents a method to a consumer that is safe, 
effective, and inexpensive.  Disadvantages do occur, however, and the multiple injections 
can be difficult with mares that have an aversion to needles, though most of the mares in 
the study tolerated needles well.  Mares are frequently used in the performance industry 
and much time, training, and expense is invested in these animals.  Suppressing estrus 
using exogenous oxytocin is an effective and desirable method that will allow horse 
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